[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,420,0,25,[9,47,73,120,145,168,200,228,250,268,295,317,346,371,395,418,442,465,488,510,536,562,588,615,640],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100647866","screening-protocol-100647866",false,"NCT07712874","Screening Protocol","Screening Evaluation of Volunteers for Studies of Pain","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated interest in, and availability for, participating in NCCIH studies and willingness to comply with the procedures of this protocol.\n* At least 12 years of age\n* No identified acute health concerns (i.e. symptomatic uncontrolled diabetes mellitus, congestive heart failure, liver cirrhosis, ongoing cancer (excluding skin basal cell carcinoma and squamous cell carcinoma) as evidenced by screening medical history\n* Ability to understand and able to provide written informed consent form.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Have active medical or psychiatric health issues that create additional and substantial adverse risks related to study procedures. Medical examples are the acute complications of medical disease, such as asymptomatic hypertensive urgency, diabetic ketoacidosis, symptomatic hyperthyroidism, and unstable angina. Psychiatric examples are the acute complications of psychiatric disease, such as acute mania, paranoid delusions, or having active panic attacks.\n* Ongoing substance uses disorder or illicit substance use\n* Pregnancy\n\nAdditional exclusion from optional QST procedures:\n\nHas a major medical condition or medical history that in a clinician's assessment could affect heat sensitivity, pain thresholds, or ability to comply with study procedures. This may include cardiovascular, autonomic, or neurological conditions (including stroke and blindness or deafness, a history of brain damage, or psychosis).",true,"ALL","12 Years","100 Years",{"count":22,"type":23},10000,"ESTIMATED","OBSERVATIONAL","This study is a screening evaluation for volunteers who are interested in participating in National Center for Complementary and Integrative Health (NCCIH) research studies about pain and related processes, such as emotion, mood, and decision-making. Screening may include review of medical history, physical exam, vital signs, questionnaires, blood and urine tests, and optional sensory testing to better understand pain and related symptoms. The purpose is to identify and characterize healthy volunteers and people with pain who may be eligible for future NCCIH research studies. This screening study does not test a treatment and has no formal hypothesis.",[27],"Pain",[29,30,31,32,33],"Pain screening","Healthy Volunteers","Quantitative Sensory Testing","Ecological Momentary Assessment","Patient-Reported Outcomes","NOT_YET_RECRUITING","2026-08-20",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":23},"2026-08-26",{"date":42,"type":23},"2050-07-02",{"name":44,"class":45},"National Center for Complementary and Integrative Health (NCCIH)","NIH",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100607631","pivotal-study-on-the-novabloc-system-for-patients-undergoing-primary-total-knee-arthroplasty-100607631","NCT07191067","Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty","A Multi-Center Two-Arm, Randomized, Blinded, Sham-Controlled Trial to Determine the Safety and Efficacy of the NOVABLOC System on Postoperative Pain, Functional Recovery and Opioid Use in Patients Undergoing Primary Total Knee Arthroplasty","NOVABLOC-TKA","Inclusion Criteria:\n\n1. Male or non-pregnant females age ≥ 21 years of age;\n2. Has an underlying diagnosis of osteoarthritis indicated for a primary unilateral TKA according to established treatment guidelines;\n3. Able and willing to provide and document informed consent and Authorization for Release of Protected Health Information (PHI);\n4. Able and willing to comply with all trial tests, procedures, assessments, and follow-up visits for up to 45 days.\n5. Able to read and understand instructions and information presented in English.\n\nExclusion Criteria:\n\n1. Chronic opioid use (average ≥ 30 oral morphine equivalents \u002F day) ≤ thirty (30) days of the TKA procedure;\n2. Extended-release or long-acting opioid (e.g. buprenorphine, Morphine ER, etc.) use ≤ thirty (30) days of the TKA procedure;\n3. History of substance abuse or misuse;\n4. History of significant cardiac disease (e.g. ejection fraction ≤ 50%; coronary intervention ≤ six (6) months; significant valvular abnormalities);\n5. Prior radiofrequency ablation or cryotherapy for pain on the operative knee;\n6. Prior TKA on the operative knee;\n7. BMI \\> 40;\n8. History of neurological, neuromuscular or neuropathic disease that would confound the study results, including chronic pain conditions;\n9. Have an active implanted biomedical device (such as cardiac pacemaker, insulin pump, pain stimulator, implantable cardioverter defibrillator) or cochlear \\[ear\\] stimulator);\n10. History of hip or knee dislocation or bone fractures on the operative leg;\n11. Sepsis or systemic infectious illness; local infection of skin or subcutaneous tissues where procedural access is required including thigh, hip or groin;\n12. Concomitant medical or psychiatric illness that could compromise evaluation or treatment, including anxiety (GAD-7 score \\>10) or depression (PHQ-9 score \\>15);\n13. Pregnant, actively planning a pregnancy or breast-feeding a child;\n14. Uncontrolled diabetes (A1C \\> 7.5%);\n15. History of bleeding disorder;\n16. Participating in another clinical trial\u002Finvestigation within 45 days prior to signing informed consent.","21 Years",{"count":57,"type":23},120,"INTERVENTIONAL",[60],"NA","Multi-center, randomized, blinded, sham-controlled study to determin the safety and efficacy of the NOVABLOC system on post-operative pain in patients undergoing TKA procedures.",[27],"RECRUITING",{"date":37,"type":38},{"date":66,"type":38},"2025-09-30",{"date":68,"type":23},"2026-12-31",{"name":70,"class":71},"Synaptrix, Inc.","INDUSTRY",5,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":17,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":119},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878","NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study","0 Years","20 Years",{"count":84,"type":23},5000,"The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[87,88,89,90,27,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome",{"date":37,"type":38},{"date":113,"type":38},"2020-03-05",{"date":115,"type":23},"2026-12",{"name":117,"class":118},"Duke University","OTHER",52,{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":58,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":46},"100243356","neural-and-psychological-mechanisms-of-pain-perception-100243356","NCT02446262","Neural and Psychological Mechanisms of Pain Perception","* INCLUSION CRITERIA:\n* Healthy\n* Between 18 and 50 years old\n* Fluent in English\n* Able to provide written informed consent.\n\nEXCLUSION CRITERIA (all sub-studies):\n\n* Unable to comply with study procedures or follow-up visits.\n* Has a major medical condition or medical history that in a clinician's assessment could affect heat sensitivity, pain thresholds, or ability to comply with study procedures. This may include cardiovascular, autonomic, or neurological conditions, including stroke, blindness, deafness, a history of brain damage, or a chronic systemic disease (e.g., diabetes).\n* Has a current mood disorder, anxiety disorder, or substance use disorder, or has a history of psychosis, hospitalization for a mental health condition, or recurrent psychiatric episodes.\n* Has a medical condition that in a clinician's assessment might affect somatosensation (e.g., Raynaud's disease, peripheral neuropathy, or circulatory disorder).\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months).\n* Has a dermatological condition affecting the testing region such as scars, burns, or recent tattoos that might influence cutaneous sensibility.\n* Regular use of prescription medication that has a significant effect on pain or heat perception. Excluded medications include central-acting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbituates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an \"as needed\" basis is acceptable as long as the last dose taken was within 5 half-lives of testing.\n* Is pregnant.\n* NIH staff member who is a subordinate\u002Frelative\u002Fco-worker of any investigator on the protocol.\n\nEXCLUSION CRITERIA (fMRI sub-studies):\n\n* Individuals with conditions that could pose a risk relating to the safety of the fMRI procedure or pain stimulation will be excluded from the MRI portion of the protocol, but may participate in the non-fMRI sessions (with the exception of pregnant women). Such conditions include:\n\n  * Those with ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body.\n  * Those with an abnormality on a structural MRI.\n  * Those with an implanted cardiac pacemaker or auto-defibrillator.\n  * Those with an insulin pump.\n  * Those with irremovable body piercing.\n  * Pregnant women (based on urine test completed within 24 hours prior to scan).\n* Individuals who are left-handed (based on self-report or score on handedness questionnaire) will be excluded from fMRI substudies.\n\nEXCLUSION CRITERIA (placebo analgesia sub-studies):\n\n-Participation in an NIH study of analgesia, as gleaned from CRIS.","18 Years","50 Years",{"count":129,"type":23},550,[60],"Background:\n\n\\- Painful stimuli cause changes in a network of brain regions called the \"Pain Matrix.\" But most of these regions respond to many other stimuli, not just pain. Researchers want to understand how different factors influence pain. They want to test what happens when people expect different levels of pain and receive treatments that can modify pain. They want to see if these factors influence decisions about pain and how the body responds to it. They also want to compare pain with responses like taste and vision.\n\nObjectives:\n\n\\- To better understand how pain and emotions are processed and influenced by psychological factors.\n\nEligibility:\n\n\\- Healthy volunteers ages 18-50.\n\nDesign:\n\n* This study requires 1 to 2 clinic visits that last 1 to 3 hours.\n* Participants will be screened with medical history and physical exam.\n* Some participants will have one or more magnetic resonance imaging (MRI) scans of their brain. For MRI, participants will lie on a table that slides in and out of a cylinder. The scanner makes loud knocking noises. They will get earplugs.\n* Participants' heart activity will be recorded with electrocardiogram. Their pulse, sweating, and breathing will be monitored.\n* Some participants will take a taste test. Others may perform simple tasks. Others may receive pain in their arm, leg, or hand. The pain will come from heat or electric shocks. Others may judge pain using a topical pain-relieving cream. Some of these tests may be given during MRI.\n* Participants will fill out questionnaires.\n* The study will last 3 years.",[27,133,30],"Normal Physiology",[27,135,136,137,138],"Visual Analogue Pain Scale","Placebo","Affective Neuroscience","Functional Magnetic Resonance Imaging (fMRI)",{"date":37,"type":38},{"date":141,"type":38},"2015-06-11",{"date":143,"type":23},"2027-02-20",{"name":44,"class":45},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":151,"minAge":126,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":58,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":46},"100634672","phase-4-diphenhydramine-as-an-adjunct-to-moderate-sedation-for-procedural-first-trimester-abortions-100634672","NCT07542730","Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions","Inclusion Criteria:\n\n* Adults age 18 years and older\n* Desire procedural abortion with moderate sedation\n* Gestational age less than or equal to 13 weeks\n* Intrauterine pregnancy or pregnancy of unknown location\n* Body mass index less than or equal to 40\n\nExclusion Criteria:\n\n* Desire medical abortion or desire to continue pregnancy\n* Gestational age greater than 13 weeks\n* Body mass index greater than 40\n* Age younger than 18 years\n* Confirmed ectopic pregnancy\n* Medical condition that is a contraindication to moderate sedation as determined by the treating clinician","FEMALE",{"count":153,"type":23},98,[155],"PHASE4","This single center, double blind, randomized controlled trial will evaluate whether adding intravenous diphenhydramine to a standard moderate sedation regimen improves pain control during first trimester procedural abortion. Participants undergoing uterine aspiration at less than 13 weeks gestation will be randomized 1 to 1 to receive standard moderate sedation with midazolam and fentanyl plus either diphenhydramine 50 mg intravenously or matching placebo. The primary outcome is participant reported pain during uterine aspiration measured by a 100 mm Visual Analog Scale.",[27,158,159],"Abortion","Anxiety","2026-08-19",{"date":37,"type":38},{"date":163,"type":38},"2026-06-29",{"date":165,"type":23},"2027-02",{"name":167,"class":118},"University of Rochester",{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":58,"phases":178,"briefSummary":179,"conditions":180,"keywords":186,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100591026","phase-4-effect-of-magnesium-on-neuromonitoring-100591026","NCT06975072","Effect of Magnesium on Neuromonitoring","Pharmacokinetics and Impact of Magnesium Sulfate on Neuromonitoring in Spinal Surgery","MgNm","Inclusion Criteria:\n\nAdult patients (\\>18 years of age) undergoing open thoracolumbar fusion with planned neuromonitoring\n\nExclusion Criteria:\n\n1. Patients with a history of significant cardiac disease (LVEF \\\u003C35%, 2nd\u002F3rd-degree block without a pacemaker, or significant arrhythmia)\n2. Patients with kidney disease (GFR \\\u003C30), or hepatic dysfunction (history of cirrhosis)\n3. Allergy or sensitivity to magnesium\n4. Patient with neuromuscular disease such as myasthenia graves",{"count":177,"type":23},40,[155],"Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Transcranial Motor Evoked Potentials (TcMEPs) monitor the integrity of the motor pathways and are one of the most commonly used monitoring modalities in spinal surgery. Because inhaled anesthetics can negatively affect the ability to monitor TcMEPs, anesthesiologists commonly use a combination of propofol and opioids to maintain the anesthetic state. Additionally, anesthesiologists will frequently administer intravenous infusions of medications that can decrease postoperative pain and opioid use (called opioid-sparing adjuncts) because spinal surgeries result in significant postoperative pain. Despite the increasing use of these agents, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. Magnesium (Mg), a N-methyl-d-aspartate receptors (NMDA) receptor antagonist, is one of the adjuncts with robust data supporting clinical efficacy to decrease pain and opioid use on TcMEPs. Mg has been used clinically for decades. The investigators commonly utilize intravenous magnesium as a component of our spinal anesthesia protocol. However, there is only a single case report that discusses the effects of Mg on TcMEPs. Here the investigators propose a prospective clinical trial to quantitatively assess the effects of various Mg plasma levels on TcMEPs. There is a lack of literature on the pharmacokinetics of magnesium in non-pregnant patients.",[181,27,182,183,184,185],"Spine","Spine Surgery","Spine Surgery With Neuromonitoring","Spine Surgery With Motor Evoked Potential Monitoring","Spine Fusion",[187,188,189,190,191,192],"spine","spine surgery","spine fusion","magnesium","neuromonitoring","motor evoked potential monitoring",{"date":37,"type":38},{"date":195,"type":38},"2025-07-01",{"date":197,"type":23},"2026-12-30",{"name":199,"class":118},"University of California, San Francisco",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":58,"phases":209,"briefSummary":210,"conditions":211,"keywords":216,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":46},"100649992","feasibility-and-acceptability-of-empowered-relief-for-american-indians-with-pain-during-and-after-cancer-treatment-100649992","NCT07742449","Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment","ejames3","Inclusion Criteria:\n\n* Identifies as American Indian\n* Has history of a cancer diagnosis\n* Is currently undergoing or has completed active cancer treatment\n* Experiences body pain most or every day\n* Pain duration at least 3 months\n* English fluency\n\nExclusion Criteria:\n\n* Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the Zoom-based ER class)\n* Life-threatening acute illness (e.g., infection, heart attack, injury)\n* No access to a computer, a smartphone, or a tablet",{"count":208,"type":23},70,[60],"This project will evaluate the feasibility and acceptability of Empowered Relief (ER) among American Indian adults who are currently receiving or have completed active cancer treatments at Stephenson Cancer Center (SCC). ER is a single-session, Zoom-based, 2-hour, skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily practice. ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety at 3 and 6 months post-treatment. Because of its brief, didactic nature and Zoom delivery, ER can accommodate large class sizes and may address accessibility disparities among underserved cancer populations. While ER is being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad, it has not been tested in American Indians with cancer.",[212,27,213,214,215],"Cancer","Pain Management","Chronic Pain","American Indian or Alaska Native",[212,217,27,214,218,219],"Cancer Survivor","Native American","American Indian","2026-08-18",{"date":35,"type":38},{"date":223,"type":23},"2026-08-01",{"date":225,"type":23},"2027-12",{"name":227,"class":118},"University of Oklahoma",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":58,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":46},"100305620","sociocultural--biobehavioral-influences-on-pain-expression-and-assessment-100305620","NCT03258580","Sociocultural & Biobehavioral Influences on Pain Expression and Assessment","* INCLUSION CRITERIA:\n\nAll Sub-Studies:\n\n* Healthy\n* Between 18 and 60 years old\n* Fluent in English\n* Able to provide written informed consent\n\nEXCLUSION CRITERIA:\n\nAll Sub-Studies:\n\n* Unable to comply with study procedures\n* Has a major-medical condition or medical history that in a clinician's assessment could affect ability to comply with study procedures, including neurological conditions (including stroke, blindness or deafness, or a history of brain damage)\n* Has a current mood disorder, anxiety disorder, or substance use disorder, or has a history of psychosis, hospitalization for a mental health condition, or recurrent psychiatric episodes.\n* NIH staff member who is a subordinate\u002Frelative\u002Fco-worker of any investigator on the protocol\n* Prior completion of a different sub-study within this protocol.\n* Is born outside of the states or territories of the United States of America\n* Does not currently reside in a state or territory of the United States of America\n\nSub-study 1:\n\n* Has a major-medical condition or medical history that in a clinician's assessment could affect heat sensitivity or pain thresholds. This may include cardiovascular, autonomic, or neurological conditions or a chronic systemic disease (e.g., diabetes)\n* Has a medical condition that in a clinician's assessment might affect somatosensation (e.g., Raynaud's disease, peripheral neuropathy, or circulatory disorder)\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)\n* Has a dermatological condition affecting the testing region, such as scars, burns, or recent tattoos that might influence cutaneous sensibility\n* Regular use of prescription medication that has a significant effect on pain or heat perception. Excluded medications include central-acting agents such as opiates (morphine, tramadol), antidepressants (amitriptyline, duloxetine, milnacipran), anticonvulsants (gabapentin, pregabalin), anxiolytics (barbituates, benzodiazepines), hypnotics (zolpidem, sodium oxybate), antipsychotics (valproate, lithium, olanzapine), antimigraine agents (sumatriptan, ergotamine), and muscle relaxants (cyclobenzaprine, carisoprodol). Use of analgesic medications, such as non-steroidal anti-inflammatories, salicylates, and acetaminophen, taken on an \"as needed\" basis is acceptable as long as the last dose was not taken was within 5 half-lives of testing.\n* Is left handed\n\nSub-study 4, FMRI participants:\n\n* Has a current chronic pain condition or has had chronic pain in the past (painful condition lasting more than six months)\n* Is left-handed\n* Any FMRI contraindications, including:\n\n  * Ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body.\n  * Implanted cardiac pacemaker or auto-defibrillator.\n  * Insulin pump.\n  * Irremovable body piercing.\n* Pregnant women (based on urine test completed within 24 hours prior to scan).\n* Those with an abnormality on a structural MRI that has functional consequences based on clinician assessment.","60 Years",{"count":236,"type":23},700,[60],"Objective\n\nThe current proposal investigates behavioral, psychophysiological, and social processes that may help explain biases and disparate outcomes in pain. Health disparities, or health outcomes that adversely affect disadvantaged populations, are pervasive and apparent in many diseases and symptoms, including pain. Pain is the number one reason individuals seek medical treatment. Health disparities in pain encompass both differences in pain experience and treatment for pain. For instance, research indicates that Black individuals report increased pain and have reduced pain tolerance relative to White individuals, yet doctors are less likely to treat minority patients pain and underestimate their pain experience. This project aims to address this systemic discrepancy by focusing on interpersonal processes that may contribute to these disparities, including socially-relevant responses to pain (i.e. pain expression) and pain assessment (e.g. visual attention). The proposed research aims to determine whether the study of pain expressions and their assessment can yield insights on how social factors shape pain and its treatment. Further, we test the efficacy of potential interventions designed to improve accuracy and reduce biases in pain assessment. If successful, this work will form the foundation of a new research program that will link the field of pain research with the field of social neuroscience, and forge new insights on the critical problem of health disparities in pain.\n\nStudy population\n\nWe will accrue up to 700 total healthy volunteers to target 240 completers\n\nDesign\n\nOur overall aim is to understand how social factors influence the assessment and management of pain, and to gain insight into psychosocial processes that may underlie health disparities in pain. We propose a series of studies designed to test these links. First, we will measure pain perception and physiological responses to painful stimuli in a diverse group of individuals to test for sociocultural and biological influences on pain and pain-related responses. In subsequent studies, new participants (\"perceivers\") will view images of these initial participants (\"targets\") and will provide estimates of 'targets' pain experience. We will measure a) whether perceivers can accurately estimate 'targets' pain experience; b) whether accuracy differs as a function of similarity between target and perceiver (ingroup vs outgroup); and c) whether individuals can improve accuracy through feedback.\n\nOutcome measures\n\nPrimary outcome measures for all experiments will be decisions about pain (experienced by self or other) measured with visual analogue scales, reaction time, and\u002For categorical judgments (pain\u002Fno pain). We will also measure physiological responses (e.g., facial muscle response, skin conductance, pupil dilation) and brain responses using functional magnetic resonance imaging (fMRI) as secondary outcome measures. We will test whether pain and pain-related responses varies as a function of sociocultural\u002Fdemographic factors (e.g. race, ethnicity, sex) and whether accuracy in assessing others' pain is influenced by group similarity (i.e. ingroup vs. outgroup) and training (e.g. performance-related feedback)....",[133,30,27],[27,135,241,242,243],"Healthy Volunteer","EYE TRACKING","Eye Movement",{"date":160,"type":38},{"date":246,"type":38},"2018-05-09",{"date":248,"type":23},"2027-05-30",{"name":44,"class":45},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":46},"100263310","clinical-and-scientific-assessment-of-pain-and-painful-disorders-100263310","NCT02707029","Clinical and Scientific Assessment of Pain and Painful Disorders","* INCLUSION CRITERIA:\n* Are \\>= 12 years of age\n\nEXCLUSION CRITERIA:\n\n* Have difficulties with communication that make subjective pain assessment impossible or unreliable.\n* Have acute medical or psychiatric health issues that create additional and substantial adverse risks related to study procedures. Medical examples are the acute complications of medical disease, such as asymptomatic hypertensive urgency, diabetic ketoacidosis, symptomatic hyperthyroidism, and unstable angina. Psychiatric examples are the acute complications of psychiatric disease, such as acute mania, paranoid delusions, or having acute panic attacks.\n* Are participating in other ongoing research protocols such that phenotypic measurements would interfere with the conduct of an ongoing protocols or the receipt of a research treatment would influence the phenotypic measurements.\n* Employees or staff that work at NCCIH.\n* Pregnant women","120 Years",{"count":22,"type":23},"Background:\n\nResearchers want to better understand pain by studying people with and without different kinds of pain. To do this, researchers will expose people to pleasant and unpleasant sensations. They will ask them questions about their pain. Researchers also want to see if these people are eligible for other research studies at the National Center for Complementary and Integrative Health.\n\nObjectives:\n\nTo study the experience of pain. Also to find people eligible to join other NIH studies.\n\nEligibility:\n\nPeople 12 years and older with and without pain disorders.\n\nDesign:\n\nParticipants will be screened by phone.\n\nParticipants will have one required visit lasting about 2 hours. This may include:\n\n* Medical history\n* Physical exam\n* Questionnaires about themselves and their pain experience\n* Blood and urine tests\n* MRI: They will lie on a table that slides into a cylinder. They will feel different sensations while completing tasks on a computer. This lasts 15 minutes to 2 hours.\n* Quantitative sensory testing: They will be exposed to different pictures, sounds, tastes, and smells. They will also be exposed to pleasant and unpleasant sensations. These could include:\n\n  * Burning, itching, or cold sensations\n  * Pinpricks\n  * Pressure and pinches\n* Electrocardiogram: Stickers on the chest record heart activity.\n* Straps placed around the chest to measure breathing.\n* Small sensors on the fingers or palms to measure pulse and sweating.\n\nParticipants may have up to 12 other outpatient study visits.\n\nParticipants may be recorded at the visits.",[133,27],[14,27,261],"Phenotypes",{"date":160,"type":38},{"date":264,"type":38},"2016-07-22",{"date":266,"type":23},"2027-02-09",{"name":44,"class":45},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":234,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":58,"phases":278,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":46},"100445527","a-primary-care-based-psychosocial-intervention-to-improve-cognitive--depression-outcomes-in-older-adults-with-mci--early-stage-ad-100445527","NCT05081596","A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD","PATH-Pain: A Primary Care-Based Psychosocial Intervention To Improve Cognitive and Depression Outcomes in Older Adults With MCI and Early Stage AD","PATH-Pain","Inclusion Criteria:\n\n* Age ≥ 60 years old\n* MCI or early stage probable or possible AD diagnosis (as defined by Albert et al or McKhann et al) al). Patients will have at least mild cognitive deficits defined by 16 ≤ MoCA ≤ 25.\n* Montgomery Asberg Depression Rating Scale (MADRS)\\[55\\] total ≥ 5, which reflects at least some mild depressive symptoms.\n* Participants will be off antidepressants, cholinesterase inhibitors or memantine or on a stable dosage for at least 12 weeks.\n* Chronic pain (neuropathic, nociceptive or mixed disorders): presence of pain on most days for at least 3 months and average pain intensity score \\>=4.\n* Clinical Dementia Rating 0.5 ≤ (CDR) ≤ 1.\n* Participant will have capacity to consent.\n* Participation of a study partner (e.g. caregiver\u002Ffamily member\u002Fsignificant other) is required.\n\nExclusion Criteria:\n\n* Deemed to have a significant suicide risk as assessed by site PI and clinical team.\n* Deemed too unstable medically or neurologically to safely enroll in a research trial.\n* Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy.\n* Requiring psychiatric hospitalization at baseline for safety.\n* Lack of English fluency.",{"count":277,"type":23},100,[60],"The purpose of the study is to examine the effect of Problem Adaptation Therapy for Pain (PATH-Pain) on cognitive functioning, depression and pain-related disability in 100 older adults with cognitive impairment, chronic pain, and depression. The study will test if PATH-Pain has better cognitive, affective, and functional outcomes than Attention Control Usual Care.",[281,27,282],"Depression","Cognitive Impairment",[284,285,286],"Older Adults","Mild Cognitive Impairment","Early Stage Alzheimer's Disease","2026-08-17",{"date":35,"type":38},{"date":290,"type":38},"2022-06-03",{"date":292,"type":23},"2027-07-31",{"name":294,"class":118},"Weill Medical College of Cornell University",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":58,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":316},"100634352","phase-4-evaluation-of-pain-treatment-after-total-knee-arthroplasty-100634352","NCT07538570","Evaluation of Pain Treatment After Total Knee Arthroplasty","A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty","Key Inclusion Criteria:\n\n* Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg\u002Fm\\^2)\n* Scheduled to undergo an elective primary unilateral TKA surgery\n\nKey Exclusion Criteria:\n\n\\- History of previous TKA surgery on incident side\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.","80 Years",{"count":304,"type":23},60,[155],"The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).",[27],"2026-08-14",{"date":220,"type":38},{"date":311,"type":38},"2026-04-24",{"date":313,"type":23},"2027-01-30",{"name":315,"class":71},"Vertex Pharmaceuticals Incorporated",2,{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":18,"minAge":324,"maxAge":19,"enrollmentInfo":325,"targetDuration":4,"studyType":58,"phases":327,"briefSummary":328,"conditions":329,"keywords":336,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":316},"100610081","feasibility-study-of-a-guided-imagery-therapy-mobile-application-for-functional-abdominal-pain-disorders-in-children-100610081","NCT07222943","Feasibility Study of a Guided Imagery Therapy Mobile Application for Functional Abdominal Pain Disorders in Children","Open-Labelled Feasibility Study of a Guided Imagery Therapy Mobile Application for Functional Abdominal Pain Disorders in Children","Inclusion Criteria:\n\n* Texas Children's Pediatrics patients 7 to 12 years old at enrollment\n* A Rome IV Functional Abdominal Pain Disorder as defined by a 2-week abdominal pain and stooling diary\n* Both children and their primary caregivers must be able to read and communicate in English proficiently to understand the intervention's audio therapy sessions and psychometric instruments.\n\nExclusion Criteria:\n\n* Previous abdominal surgeries\n* Co-morbid conditions associated with abdominal pain (e.g., cystic fibrosis)\n* Autism\n* Significant development delay\n* Psychosis\n* Prior experience with cognitive behavioral therapy or guided imagery therapy to treat chronic abdominal pain\n* Alarm symptoms that warrant further medical evaluation (e.g., blood in stool)","7 Years",{"count":326,"type":23},63,[60],"Chronic abdominal pain is common among children, and the majority of cases are attributed to functional abdominal pain disorders. One approach to treating these disorders is by using psychological therapies. This clinical trial aims to see how well pre-recorded guided imagery therapy sessions help children's abdominal pain when delivered via a mobile application (app) on a smartphone or tablet.\n\nParticipants will complete a baseline abdominal pain and stooling diary to determine eligibility, as well as other surveys. Eligible participants will be given access to the guided imagery therapy mobile application.\n\nThis intervention asks participants to listen to a 10- to 15-minute GIT session 5 out of 7 days per week for 8 weeks, in addition to their usual care for their abdominal pain. Then, participants will complete another abdominal pain and stooling diary, along with other psychometric surveys, at the end of this intervention period. Participants will also collect another diary and surveys 3 months post-treatment.",[330,331,332,333,334,27,335],"Functional Abdominal Pain Disorders","Irritable Bowel Syndrome (IBS)","Functional Gastrointestinal Disorders (FGIDs)","Gastrointestinal and Digestive Disorder","Abdominal Pain\u002F Discomfort","Functional Dyspepsia",[337,338],"abdominal pain","irritable bowel syndrome",{"date":287,"type":38},{"date":341,"type":23},"2026-09-01",{"date":343,"type":23},"2027-04-30",{"name":345,"class":118},"Baylor College of Medicine",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":58,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":369,"locationsCount":46},"100638123","active-vs-passive-vr-during-office-based-ent-procedures-100638123","NCT07599826","Active vs. Passive VR During Office-based ENT Procedures","Active vs. Passive Virtual Reality for Reducing Pain and Anxiety During Office-based ENT Procedures","Inclusion Criteria Active and Passive VR:\n\n* Individuals 18 years old and older are included\n* Individuals undergoing the following common office-based ENT procedures: turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation (RhinAer\u002FVivAer), nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection\n* Able to consent\n* English speaking\n\nExclusion Criteria Active VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, vertigo, or inability to use a handheld controller\n* Any records flagged \"break the glass\" or \"research opt out.\"\n\nExclusion Criteria Passive VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, or vertigo\n* Any records flagged \"break the glass\" or \"research opt out.\"",{"count":354,"type":23},132,[60],"The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars-Sinai.",[27,159,358,359,360,361,362,363],"Chronic Rhinosinusitis (CRS)","Nasal Obstruction","Nasal Polyp","Eustachian Tube Dysfunction","Dysphonia","Subglottic Stenosis (SGS)","2026-08-13",{"date":287,"type":38},{"date":367,"type":23},"2026-09",{"date":225,"type":23},{"name":370,"class":118},"Cedars-Sinai Medical Center",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":58,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":46},"100601585","pain-intervention-with-needling-pilot-of-integrated-neuromodulation-techniques-100601585","NCT07112404","Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques","PINPOINT Study: Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques","PINPOINT","Inclusion Criteria:\n\n* Both males and females between the ages of 18 and 65 will be included in this study.\n\nPhase 1 Inclusion criteria\n\n\\- Healthy adults who report no pain for more than 1 day in the past 3 months in their lumbar region. Lumbar region will include posterior lumber musculature, lumbar spine, sacroiliac pain, or superior gluteal area pain.\n\nPhase 2 Inclusion criteria\n\n* Adults experiencing chronic low back pain. Chronic low back pain will be identified as having pain the lumbar region for at least 3 months. The pain may be constant or episodic in nature.\n* Participants will be included if they experience pain at least 75% of the days in the past 3 months. All pain levels will be included. Lumbar region will include posterior lumber musculature, lumbar spine, sacroiliac pain, or superior gluteal area pain.\n\nExclusion Criteria:\n\n* Individuals who are currently seeking any form of medical treatment for lumbar conditions beyond routine physician follow-up appointments in order to avoid confounding variables, regardless of pain-free status. These may include, but are not limited to, seeking treatment from a chiropractor, acupuncturist, or massage therapist or medical procedures such as injections into the lumbar region for pain.\n* Additionally, those with previous lumbar surgeries or those with previous major injuries to the lumbar spine that may have resulted in structural abnormalities that may compromise needle placement will be excluded. If surgical procedures did not alter structural alignment, then it will be allowed. For example, an approved procedure may include discectomy or nerve ablation, while a not approved procedure would include a lumbar fusion or scoliosis rod placement.\n* Additionally, if a person is experiencing radicular symptoms from a back injury, despite not feeling the symptoms in the lumbar region, will not be considered. Radicular symptoms will be defined as those present past the knee and\u002For electrical in nature. Individuals with neurological conditions or those who need the services of another due to cognitive deficits will not be considered for this study.\n* Furthermore, as this study relies on an intact sensory system, participants with conditions that may affect sensory processing (e.g., peripheral neuropathy, skin conditions, or circulatory disorders) will be excluded through careful screening.\n\nAdditional exclusion criteria\n\n* Will include the following conditions identified as contraindications for dry needling: those with impaired sensitivity, taking anticoagulants, a compromised immune system, a local or systemic infection, an active tumor, history of lymph node removal, history of autoimmune disease, allergy to metals such as nickel or chromium, history of cosmetic procedures in the area, pregnant individuals, or osteoporosis.\n* Non-English-speaking subjects will be excluded from the study due to the need to understand any communication while dry-needling procedures are taking place.","65 Years",{"count":381,"type":23},42,[60],"The study will be conducted on site in Galveston, Texas, United States. Study-related assessments and procedures will be performed at the designated clinical study site by qualified study personnel in accordance with the study protocol and applicable regulatory requirements.\n\nThe study's purpose is to determine the effects of three different dry needling sessions on pain and quality of life for those with chronic low back pain. Dry needling is a therapeutic procedure in which a very thin, monofilament needle is inserted through the skin to reach a target tissue like a muscle to help reduce pain, improve muscle activation, and increase blood flow. Dry needling has also been shown to improve nervous system function.",[27,385,386,387],"Back Pain","Lower Back Pain","Quality of Life",{"date":287,"type":38},{"date":390,"type":38},"2025-10-23",{"date":392,"type":23},"2027-09",{"name":394,"class":118},"The University of Texas Medical Branch, Galveston",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":20,"enrollmentInfo":402,"targetDuration":4,"studyType":58,"phases":404,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":316},"100568590","optimizing-patients-comfort-during-scleral-indentation-100568590","NCT06683209","Optimizing Patient's Comfort During Scleral Indentation","Comparison of Scleral Indentation Instruments and Impact on Patient Comfort","Inclusion Criteria:\n\n* Symptomatic posterior vitreous detachment with or without vitreoretinal pathology\n\nExclusion Criteria:\n\n* Monocular status.\n* Media opacity which precludes view of the peripheral retina.\n* Inadequate examination (cooperation with examination, inability to achieve all directions of gaze).\n* Underlying oculodynia (recent surgery, intraocular inflammation, abnormal intraocular pressure, ocular dysesthesia syndromes (ocular, adnexal or orbital).\n* History of pain-sensitizing conditions or current analgesic use.\n* Previous scleral indented examination poorly tolerated.",{"count":403,"type":23},75,[60],"The scleral depression exam is an important routine technique for evaluating the retinal periphery for various reasons. During this examination, an instrument is used to bring the anterior part of the retina into the physician's field of view. The downside of this technique is the discomfort it may cause the patient. Different instruments can be used to depress the sclera.\n\nThe objective of this research is to compare three commonly used scleral depressors based on their performance for the ophthalmologist and the discomfort they subjectively induce in patients.\n\nPatients will be randomly allocated to one of three examination groups:\n\nGroup A: One eye examined with the Schocket scleral depressor, the other eye with the Josephberg-Besser scleral depressor.\n\nGroup B: One eye examined with the Schocket scleral depressor, the other eye with the cotton-tip applicator.\n\nGroup C: One eye examined with the cotton-tip applicator, the other eye with the Josephberg-Besser scleral depressor.",[27],[408,409,410],"Schocket","Josephberg-Besser","Cotton tip applicator",{"date":287,"type":38},{"date":413,"type":23},"2027-07-01",{"date":415,"type":23},"2028-07-30",{"name":417,"class":118},"University of Alberta",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":58,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":4},"100652527","codepad-iii-collaborative-outcomes-of-depression-and-pain-associated-with-delivery-iii-100652527","NCT07773259","CODEPAD-III (Collaborative Outcomes of DEpression and Pain Associated With Delivery-III)","Collaborative Psychological Model for Management of Postnatal Depression and Persistent Postpartum Pain After Childbirth: CODEPAD-III (Collaborative Outcomes of DEpression and Pain Associated With Delivery-III)","CODEPAD-III","Inclusion Criteria (Mothers):\n\n* Healthy (American Society of Anesthesiologists (ASA) physical status II);\n* Parturient women at term (36 weeks' gestation or more, nulliparous and multiparous);\n* With a singleton fetus;\n* Planning to have childbirth and delivery at study site;\n* Patients with prior mental health history, and current active psychiatric care will also be recruited.\n\nInclusion Criteria (Fathers):\n\n* Identified partner (e.g., husband or significant other) of the enrolled pregnant patient;\n* Aged 21 years and above;\n* Able to understand the study procedures and willing to participate in the 8 weeks postpartum assessment.\n\nExclusion Criteria (Mothers):\n\n* History of intravenous drug or opioid abuse;\n* Previous history of chronic pain syndrome.\n\nExclusion Criteria (Fathers):\n\n* Unable to provide informed consent (e.g., cognitive impairment, language barriers without available translation support);\n* Any condition that, in the opinion of the investigators, would make participation inappropriate (e.g., severe psychiatric or medical condition).",{"count":427,"type":23},3470,[60],"The childbirth process is associated with increased risk of having depression and persistent pain which may have adverse effects to mothers and their babies. There is a lack of routine effective programs in current healthcare practice to address, risk stratify and reduce depression and persistent pain after childbirth.\n\nThe study site proposes a Collaborative Psychological Model (CPM) consisting of music listening, customized mobile application on psychological strategies, telephone-based support, with monitoring (mobile electronic surveys, wearable-based vital sign monitoring) to effectively prevent, detect, monitor, and treat depression and persistent pain after childbirth. The study will determine if using the CPM will reduce the risk of having depression associated with childbirth. The study will also find out whether the CPM will reduce the depressive symptoms in women who undergo labor that may have increased depression risk. This clinical study will involve 2042 women undergoing childbirth at KK Hospital. In addition, up to 1428 patients' partners (fathers) will also be recruited for the week 8 postpartum assessment.\n\nThe study findings will improve healthcare for women in the community by incorporating digital psychological strategies to manage depression and persistent pain after childbirth. The CPM will also guide future directions to customize an individual's healthcare needs and to improve transition from hospital to community care for women after childbirth.",[281,431,27,432],"Postpartum","Mental Health","2026-08-12",{"date":160,"type":38},{"date":436,"type":23},"2026-10",{"date":438,"type":23},"2031-12",{"name":440,"class":441},"KK Women's and Children's Hospital","OTHER_GOV",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":58,"phases":451,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":46},"100375079","the-role-of-virtual-reality-during-regional-anesthesia-100375079","NCT04163809","The Role of Virtual Reality During Regional Anesthesia","Inclusion Criteria:\n\n1. Elective pre-operative patients at Cedars-Sinai Medical Center who are receiving regional anesthesia\n2. Between ages 18-64\n3. Patient must be able to provide informed consent\n\nExclusion Criteria:\n\n1. Patients under the age of 18 \\& above age 64\n2. Visual impairment\n3. Pregnant women\n4. Diagnosis of epilepsy\u002Fseizures, dementia, and\u002For cognitive impairment","64 Years",{"count":450,"type":23},80,[60],"In this study, we will analyze the role of virtual reality in acute pain and anxiety management for regional anesthesia in pre-operative patients at Cedars-Sinai Medical Center.",[159,27],[455,456,457,458],"virtual reality","anxiety","pain","regional anesthesia",{"date":308,"type":38},{"date":461,"type":23},"2027-01-01",{"date":463,"type":23},"2028-06",{"name":370,"class":118},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":17,"sex":18,"minAge":472,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":58,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":484,"leadSponsor":486,"locationsCount":46},"100647897","different-local-anesthesia-techniques-for-mandibular-primary-molar-pulpectomy-100647897","NCT07714915","Different Local Anesthesia Techniques for Mandibular Primary Molar Pulpectomy","Comparison of Computer-Controlled and Conventional Local Anesthesia Techniques on Dental Anxiety and Pain During Mandibular Primary Molar Pulpectomy: A Split-Mouth Randomized Clinical Trial","Inclusion Criteria:\n\n* Children aged 6 to 8 years.\n* Requiring bilateral pulpectomy treatment of mandibular primary molars.\n* Frankl Behavior Rating Scale score of 3 or 4.\n* American Society of Anesthesiologists (ASA) Physical Status I.\n* No known allergy to local anesthetic agents.\n* No previous experience with dental local anesthesia.\n* No signs of acute abscess or swelling in the treatment area.\n* Parent or legal guardian able to provide written informed consent and child willing to participate.\n\nExclusion Criteria:\n\n* ASA Physical Status II or higher.\n* Known allergy or contraindication to local anesthetic agents.\n* Frankl Behavior Rating Scale score of 1 or 2.\n* Children receiving psychological or psychiatric treatment.\n* Physical or intellectual disabilities that could interfere with study procedures.\n* Previous experience with dental local anesthesia.\n* Presence of acute abscess, cellulitis, or diffuse swelling in the treatment area.","6 Years","8 Years",{"count":475,"type":23},38,[60],"This study aims to compare the effects of computer-controlled local anesthesia and conventional inferior alveolar nerve block on dental anxiety and pain in children undergoing pulpectomy of mandibular primary molars. Both anesthesia techniques are routinely used in pediatric dental practice and are considered standard methods of care.\n\nChildren aged 6 to 8 years who require bilateral pulpectomy of mandibular primary molars will be included in this split-mouth randomized clinical trial. Each participant will receive both anesthesia techniques during separate treatment sessions. Dental anxiety, pain, and physiological parameters, including heart rate, blood pressure, oxygen saturation, and body temperature, will be assessed before, during, and after treatment using validated pediatric assessment scales and routine clinical measurements.\n\nThe findings of this study may help identify the anesthesia technique that provides greater comfort and reduces anxiety and pain during pediatric dental treatment, thereby improving the overall treatment experience for children.",[479,27,480],"Dental Anxiety","Pulpal Diseases","2026-08-11",{"date":433,"type":38},{"date":433,"type":23},{"date":485,"type":23},"2026-10-15",{"name":487,"class":118},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":302,"enrollmentInfo":495,"targetDuration":4,"studyType":58,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":46},"100369773","hip-arthroscopy-postoperative-opioid-demands-100369773","NCT04094701","Hip Arthroscopy Postoperative Opioid Demands","Randomized Control Trial Evaluating Postoperative Opioid Demands Following Hip Arthroscopy","Inclusion Criteria:\n\n* Adult patients age 18-80 years\n* English speaking\n* Opioid naive patient (defined as not taking opioid pills within 6 weeks prior to surgery), confirmed by checking the Illinois Prescription monitoring program\n* Primary hip arthroscopy\n* Written and informed consent for study participation\n\nExclusion Criteria:\n\n* Minors (\\\u003C18 years of age)\n* Opioid tolerant patients\n* Revision surgery\n* Prior infections of the operative joint\n* History of active malignancy within the past 5 years\n* Chronic pain conditions including low back pain, chronic pain syndrome, fibromyalgia\n* History of alcohol or other substance use disorder\n* Other disease states including rheumatologic conditions, diabetes mellitus, hypo\u002Fhyperthyroidism, depression, anxiety\n* Grade IV chondral defects",{"count":496,"type":23},170,[60],"This study will be a prospective, single-blinded, randomized controlled trial (RCT), investigating the influence of the number of opioid pills prescribed following primary hip arthroscopy. All patients who sign the consent form will be enrolled in the suited and randomized to one of the two treatment arms. The intervention group will receive 5 Norco pills, gabapentin (30 mg, once daily for 10 days following surgery), and Tylenol (1000 mg, three times daily for 10 days following surgery) while the control will receive the standard at our practice of 30 Norco pills.",[500,27,501,502],"Opioid Use","Femoral Acetabular Impingement","Labral Tear, Glenoid",{"date":364,"type":38},{"date":505,"type":38},"2020-10-21",{"date":507,"type":23},"2028-03",{"name":509,"class":118},"Rush University Medical Center",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":58,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":46},"100651141","effects-of-extracorporeal-shockwave-therapy-versus-dry-needling-on-jumpers-knee-100651141","NCT07756918","Effects of Extracorporeal Shockwave Therapy Versus Dry Needling on Jumpers Knee","Effects of Extracorporeal Shockwave Therapy Versus Dry Needling on Pain, Knee Function and Quality of Life in Jumpers Knee","Inclusion Criteria:\n\n* Participants of either gender between the age of 18-35 years with a confirmed diagnosis of jumper's knee for more than 1 month.\n* Confirmed diagnosis of jumper's knee for more than 1 month.\n* Pain NPRS (Numeric Pain Rating Scale) score greater than 4 at the first evaluation.\n\nExclusion Criteria:\n\n* Surgery around the knee joint within the last 6 months.\n* Chronic knee joint disease.\n* Knee pain management with corticosteroid injections in the last 3 months.\n* Trauma history\n* Systemic illness","35 Years",{"count":519,"type":23},48,[60],"The study is randomized and single-blinded. Ethical approval is taken from ethical committee of Riphah International University, Lahore. Participants who meet the inclusion criteria will be enrolled and allocated in group A \\& B through sealed envelope method by Non-probability Convenient random sampling technique. Subjects in Group A will receive Shock wave therapy. Group B will receive Dry needing.",[27,387,523],"Jumper's Knee",[525,526,457,527],"dry needling","extra-corporeal shock wave therapy","jumper knee","2026-08-10",{"date":481,"type":38},{"date":531,"type":38},"2025-10-15",{"date":533,"type":23},"2026-08-30",{"name":535,"class":118},"Riphah International University",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":543,"maxAge":544,"enrollmentInfo":545,"targetDuration":4,"studyType":58,"phases":547,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":46},"100650641","using-a-stress-ball-on-fear-anxiety-pain-and-satisfaction-during-allergy-testing-100650641","NCT07750236","Using a Stress Ball on Fear, Anxiety, Pain, and Satisfaction During Allergy Testing","The Effect of Watching Cartoons and Using a Stress Ball on Fear, Anxiety, Pain, and Satisfaction During Allergy Testing in Children","Inclusion Criteria:\n\n* Aged 4-10 years\n* Undergoing an allergy test for the first time\n* Voluntary participation by both the child and the parent\n\nExclusion Criteria:\n\n* The child must not have taken any medication prior to the skin test\n* The child must have a visual, hearing, or intellectual disability\n* The child must have a physical condition that would prevent them from using the stress ball","4 Years","10 Years",{"count":546,"type":23},90,[60],"This randomized controlled trial aims to evaluate and compare the effects of watching cartoons and using a stress ball on levels of fear, anxiety, pain, and satisfaction among 90 children aged 4-10 undergoing skin prick testing at the Pediatric Allergy Outpatient Clinic of Çukurova University Balcalı Hospital. Participants will be randomly allocated via a computer algorithm into three equal groups ($n = 30$ each): a cartoon-watching intervention group, a stress ball intervention group, and a control group receiving routine pediatric care. Data will be gathered using a Demographic Information Form, the Children's Fear Scale, the Children's Anxiety Scale-State, the Wong-Baker FACES Pain Rating Scale, and a Child Satisfaction Form at three time points-2 minutes prior to the test, immediately after the procedure, and at the 15th-minute post-test evaluation-through child, parent, and observer nurse assessments.",[550,159,551,27],"Child Allergy","Fear",[553,456,554,457,555],"child","fear","satisfaction",{"date":481,"type":38},{"date":528,"type":38},{"date":559,"type":23},"2027-05-10",{"name":561,"class":118},"Tarsus University",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":151,"minAge":126,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":58,"phases":571,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":586,"locationsCount":46},"100649585","lavender-sandalwood-aromatherapy-study-100649585","NCT07737392","Lavender Sandalwood Aromatherapy Study","Does Aromatherapy Improve Mood and Reduce Pain in Women After Scheduled Cesarean Procedures?","Inclusion Criteria:\n\n* Patients scheduled for a planned cesarean section\n* Undergoing pre-admission testing\n\nExclusion Criteria:\n\n* Individuals under 18 years of age\n* High-risk pregnancies\n* Patients not admitted to the postpartum unit following delivery\n* Individuals with known allergies to essential oils\n* Patients whose newborns require admission to the NICU\n* Patients originally scheduled for a cesarean section but admitted to the labor and delivery unit before the planned procedure",{"count":570,"type":23},182,[60],"The purpose of this randomized controlled study is to explore whether lavender sandalwood aromatherapy can support comfort, mood, pain relief, and overall satisfaction for participants recovering from a scheduled cesarean section without complications. The main questions this study aims to answer are:\n\n* How does lavender sandalwood aromatherapy affect participants' mood during postpartum recovery after a cesarean section?\n* Does lavender sandalwood aromatherapy help reduce pain during recovery?\n* Does lavender sandalwood aromatherapy improve participants' overall satisfaction with their recovery experience? Researchers will compare participants who receive lavender-sandalwood aromatherapy with those who do not to determine whether it improves mood, reduces pain, and enhances patient satisfaction.\n\nParticipants will be asked to:\n\n* Wear aromatherapy tabs on their gown for 24 hours.\n* Have the aromatherapy tabs applied 24 hours after the cesarean section and removed 48 hours after the cesarean section.\n* Complete surveys at 24 hours and 48 hours after the cesarean section. This will apply to both the control and intervention groups.",[27,574,575,576],"Mood","Patient Satisfaction","Scheduled Cesarean Sections",[578,27,574,579,580,581,582],"Post C\u002Fsection","Aromatherapy","Lavender","Sandalwood","Patient satisfaction",{"date":433,"type":38},{"date":367,"type":23},{"date":225,"type":23},{"name":587,"class":118},"Memorial Hermann Health System",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":598,"conditions":599,"keywords":600,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":614},"100187705","relief---a-global-prospective-observational-post-market-study-to-evaluate-long-term-effectiveness-of-neurostimulation-therapy-for-pain-100187705","NCT01719055","RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain","A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain","RELIEF","Key Inclusion Criteria:\n\n* Study candidate is scheduled to be trialed, on-label, with a commercially approved Boston Scientific neurostimulation system for pain, per local directions for use\n* Signed a valid, IRB\u002FEC-approved informed consent form\n* 18 years of age or older\n\nKey Exclusion Criteria:\n\n* Contraindicated for Boston Scientific neurostimulation system\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments",{"count":597,"type":23},4800,"To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Instructions for Use\n\n\\- and -\n\nTo evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice",[27],[601,602,603,604,605,606],"stimulation","implantable","pulse generator","back pain","chronic pain","leg pain",{"date":481,"type":38},{"date":609,"type":38},"2012-11-19",{"date":611,"type":23},"2035-05",{"name":613,"class":71},"Boston Scientific Corporation",118,{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":58,"phases":624,"briefSummary":625,"conditions":626,"keywords":630,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":46},"100617890","effect-of-dexamethasone-on-plasma-levels-of-bupivacaine-and-dexamethasone-after-a-single-injection-interscalene-nerve-block-100617890","NCT07324499","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Block.","Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone Following a Single-injection Interscalene Nerve Block: A Randomized Controlled Study","Inclusion Criteria:\n\n\\- ASA I-II patients, with a body mass index (BMI) between 20 and 34 kg\u002Fm2 scheduled for shoulder surgery requiring single-needle interscalene block\n\nExclusion Criteria:\n\n\\- Chronic opioid use, liver failure, kidney failure, allergy to protocol drugs","90 Years",{"count":177,"type":23},[60],"Recent studies have highlighted the comparative advantages of perineural dexamethasone, particularly regarding its safety profile and its ability to prolong analgesia in various peripheral nerve blocks. A recent systematic review demonstrated that perineural administration of dexamethasone significantly extends the duration of analgesia compared to intravenous administration.\n\nThe mechanism of action of perineural dexamethasone remains unclear. Moreover, there is a lack of research comparing the systemic absorption of local anesthetics administered perineurally with or without dexamethasone, and the systemic absorption and bioavailability of dexamethasone when used as a perineural adjuvant have not been studied.\n\nObjective: This study aims to compare plasma concentrations of bupivacaine following a single-shot interscalene block with dexamethasone administered either perineurally or intravenously.\n\nMethodology: A prospective, randomized, double-blind trial will be conducted involving 40 patients undergoing shoulder surgery requiring a single-shot interscalene block. Each patient will receive 20 mL of 0.25% bupivacaine combined with 8 mg of dexamethasone administered either perineurally or intravenously. Venous blood samples (5 mL) will be collected at 5, 10, 20, 40, 80, 120, and 240 minutes post-block, and one sample at discharge, to measure plasma concentrations of both enantiomers of bupivacaine (D(+)-bupivacaine and L(-)-bupivacaine) and dexamethasone.\n\nOutcomes: The study will compare plasma levels of bupivacaine between groups, characterize the pharmacokinetics of bupivacaine and dexamethasone, and assess block duration and opioid consumption.",[27,627,628,629],"Interscalene Blocks","Dexamethasone","Bupivacaine",[628,629,27,631],"Interscalene blocks","2026-08-09",{"date":433,"type":38},{"date":635,"type":38},"2026-05-19",{"date":637,"type":23},"2027-12-01",{"name":639,"class":118},"Pontificia Universidad Catolica de Chile",{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":646,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":58,"phases":650,"briefSummary":651,"conditions":652,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":655,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":46},"100610217","phase-4-the-impact-of-perioperative-lidocaine-infusions-on-enhanced-recovery-after-non-cardiac-surgery-100610217","NCT07224711","The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (IMPALA ERAS)","IMPALA ERAS","Inclusion criteria:\n\n* Age greater than or equal to 18\n* American Society of Anesthesiologists (ASA) class II-IV\n* Presenting for major elective, non-cardiac surgery on the colorectal, emergency general surgery, urology, ventral hernia, surgical oncology, or spine services on a weekday\n* First surgery in the study period (if a patient has multiple surgeries, only the first will be included)\n\nExclusion criteria:\n\n* ASA class \\>IV\n* Emergent procedures\n* Allergy or any contraindication to lidocaine infusion\n* Patient refusal\n* Unable to receive or refusal to receive a regional nerve block\n* Patients who receive an epidural due to standard of care\n* Direct transfer from operating room to ICU with endotracheal tube in place\n* Treating team determines patient ineligible prior to study drug administration\n* Same day surgery\n* Pregnancy (all female patient of child-bearing age will undergo a pregnancy test the day of surgery)",{"count":649,"type":23},2290,[155],"The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are:\n\nThe primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS).\n\nThe secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double\u002Fblurry vision, tinnitus, sedation, and adverse events requiring early cessation).",[27,653,654],"Post Operative Analgesia","Opioid Consumption, Postoperative",{"date":481,"type":38},{"date":657,"type":23},"2026-10-31",{"date":659,"type":23},"2028-10-31",{"name":661,"class":118},"Vanderbilt University Medical Center"]